Revisiting the personal protective equipment components of transmission-based precautions for the prevention of COVID-19 and other respiratory virus infections in healthcare.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
08 2023
Historique:
medline: 11 8 2023
pubmed: 10 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

The COVID-19 pandemic highlighted some potential limitations of transmission-based precautions. The distinction between transmission through large droplets vs aerosols, which have been fundamental concepts guiding infection control measures, has been questioned, leading to considerable variation in expert recommendations on transmission-based precautions for COVID-19. Furthermore, the application of elements of contact precautions, such as the use of gloves and gowns, is based on low-quality and inconclusive evidence and may have unintended consequences, such as increased incidence of healthcare-associated infections and spread of multidrug-resistant organisms. These observations indicate a need for high-quality studies to address the knowledge gaps and a need to revisit the theoretical background regarding various modes of transmission and the definitions of terms related to transmission. Further, we should examine the implications these definitions have on the following components of transmission-based precautions: (i) respiratory protection, (ii) use of gloves and gowns for the prevention of respiratory virus infections, (iii) aerosol-generating procedures and (iv) universal masking in healthcare settings as a control measure especially during seasonal epidemics. Such a review would ensure that transmission-based precautions are consistent and rationally based on available evidence, which would facilitate decision-making, guidance development and training, as well as their application in practice.

Identifiants

pubmed: 37561052
doi: 10.2807/1560-7917.ES.2023.28.32.2200718
pmc: PMC10416576
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Occup Environ Med. 2021 Jun 1;63(6):e395-e401
pubmed: 33871953
J R Soc Interface. 2009 Dec 6;6 Suppl 6:S783-90
pubmed: 19773292
Emerg Infect Dis. 2020 Jul;26(7):1592-1595
pubmed: 32284092
J Hosp Infect. 2014 Jan;86 Suppl 1:S1-70
pubmed: 24330862
Nat Med. 2022 May;28(5):1031-1041
pubmed: 35361992
Lancet Infect Dis. 2020 Aug;20(8):e198-e203
pubmed: 32479747
Interface Focus. 2021 Oct 12;11(6):20210049
pubmed: 34956601
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):606-610
pubmed: 32407303
J Hosp Infect. 2020 Nov;106(3):605-609
pubmed: 32745589
Viruses. 2022 Jul 22;14(8):
pubmed: 35893670
Anaesthesia. 2021 Nov;76(11):1465-1474
pubmed: 33784793
N Engl J Med. 2004 Apr 22;350(17):1710-2
pubmed: 15102996
J Virol Methods. 2021 Mar;289:114033
pubmed: 33285192
JAMA Netw Open. 2022 May 2;5(5):e2213606
pubmed: 35608859
Emerg Infect Dis. 2006 Nov;12(11):1657-62
pubmed: 17283614
Am J Infect Control. 2015 Sep 1;43(9):922-7
pubmed: 26122873
J Hosp Infect. 2023 Apr;134:89-96
pubmed: 36738992
Lancet Infect Dis. 2007 Apr;7(4):257-65
pubmed: 17376383
Lancet Microbe. 2021 May;2(5):e173-e174
pubmed: 33655228
JAMA Netw Open. 2021 Aug 2;4(8):e2119257
pubmed: 34347062
Nat Rev Microbiol. 2023 Mar;21(3):147-161
pubmed: 36460930
Am J Epidemiol. 1978 May;107(5):357-61
pubmed: 208415
Respir Med. 2017 Jan;122:76-80
pubmed: 27993295
Cochrane Database Syst Rev. 2020 Nov 20;11:CD006207
pubmed: 33215698
Am J Infect Control. 2007 Dec;35(10 Suppl 2):S65-164
pubmed: 18068815
J Hosp Infect. 2022 Dec;130:63-94
pubmed: 36115620
Cochrane Database Syst Rev. 2023 Jan 30;1:CD006207
pubmed: 36715243
Am J Infect Control. 2018 Dec;46(12):1329-1334
pubmed: 30029796
Antimicrob Resist Infect Control. 2022 Aug 11;11(1):102
pubmed: 35953854
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Health Res Policy Syst. 2018 May 29;16(1):45
pubmed: 29843743
Clin Microbiol Infect. 2022 Nov;28(11):1471-1476
pubmed: 35777605
J Hosp Infect. 2023 Feb;132:62-72
pubmed: 36473552
PLoS One. 2012;7(4):e35797
pubmed: 22563403
Nat Commun. 2022 Sep 23;13(1):5573
pubmed: 36151099
Lancet Infect Dis. 2021 Sep;21(9):1203-1204
pubmed: 34352224
J Infect Chemother. 2022 Jan;28(1):19-23
pubmed: 34538728
Infect Control Hosp Epidemiol. 2011 Dec;32(12):1194-9
pubmed: 22080658
BMJ. 2021 Nov 17;375:n2729
pubmed: 34789507
Am J Infect Control. 2020 Jan;48(1):46-51
pubmed: 31358421
Ann Intern Med. 2022 Dec;175(12):1629-1638
pubmed: 36442064
J Infect Dis. 1987 Sep;156(3):442-8
pubmed: 3039011
Evid Based Med. 2016 Aug;21(4):125-7
pubmed: 27339128
Ann Intern Med. 2020 Oct 6;173(7):542-555
pubmed: 32579379

Auteurs

Diamantis Plachouras (D)

European Centre for Disease Prevention and Control, Stockholm, Sweden.

Oliver Kacelnik (O)

Norwegian Institute of Public Health, Oslo, Norway.

Jesús Rodríguez-Baño (J)

CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Infectious Diseases and Microbiology division, Hospital Universitario Virgen Macarena and Department of Medicine, University of Seville/CSIC, Biomedicine Institute of Seville, Seville, Spain.

Gabriel Birgand (G)

Health Protection Research Unit, Healthcare Associated Infection and Antimicrobial Resistance, Imperial College London, London, United Kingdom.
Regional Centre for Infection Prevention and Control, Region of Pays de la Loire, Nantes, France.

Michael A Borg (MA)

Infection Control Department, Mater Dei Hospital, Msida, Malta.

Brian Kristensen (B)

Statens Serum Institut, Copenhagen, Denmark.

Jan Kubele (J)

Clinical Microbiology and ATB centre, Na Homolce Hospital, Prague, Czechia.

Outi Lyytikäinen (O)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Elisabeth Presterl (E)

Department for Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria.

Jacqui Reilly (J)

Research Centre for Health, Glasgow Caledonian University, Glasgow, United Kingdom.

Andreas Voss (A)

Department of Medical Microbiology and Infection Prevention, University Medical Centre Groningen, Groningen, the Netherlands.

Walter Zingg (W)

Charité Universitätsmedizin, Berlin, Germany.
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Carl Suetens (C)

European Centre for Disease Prevention and Control, Stockholm, Sweden.

Dominique L Monnet (DL)

European Centre for Disease Prevention and Control, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH